BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer
An erratum to this article was published (J Clin Endocrinol Metab, 16 Oct 2026 ↗)
Authors' conclusion
The ETS transcription factor EHF is associated with poor prognosis in PTC. This is potentially mediated by BRAF-induced upregulation of EHF, which in turn increases TERT expression in TERT promoter mutated cells.
Study context
- Population
- Papillary thyroid carcinoma (PTC); The Cancer Genome Atlas PTC cohort and a local validation cohortTCGA 399 · Cancer Genome Atlas PTC cohort 399 · a local validation cohort 93
- Outcome
- ETS factors in relation to clinical features, BRAFV600E and TERT promoter mutations
Methodological detailstranscriptomic analysis of TCGA PTC cohort, validation in local cohort, in vitro experiments
- Transcriptomic analysis of TCGA PTC cohort
- Validation in local cohort
- In vitro experiments
Main finding
As reported in the abstract
- TCGA: ETS1, ERG, FLI1, GABPA, EHF, ETV6 and SPDEF differentially expressed between stages I + II and III + IV
- In both cohorts, EHF consistently associated with adverse clinical features, BRAFV600E and TERT promoter mutation/expression
- In BRAFV600E-mutated PTC, high EHF expression associated with shorter disease-free survival
- Concurrent BRAFV600E, TERT promoter mutations and high EHF expression: shortest disease-free survival
- In cells with concurrent BRAFV600E and TERT promoter mutation, EHF overexpression significantly increased TERT expression; BRAF knockdown or pharmacological inhibition significantly decreased both EHF and TERT expression
- ChIP-qPCR suggested potential EHF binding in TERT promoter mutant but not wild-type cells
Original publication
BRAF-induced EHF Expression Affects TERT in Aggressive Papillary Thyroid Cancer. J Clin Endocrinol Metab. Published 26 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →